Genomic and immune profiling of breast cancer brain metastases
Amanda E.D. Van Swearingen(Duke Cancer Institute), Carey K. Anders(Duke University), Katelyn N Seale(Duke University Hospital), Marissa R. Lee(Duke University), Kouros Owzar(Duke University), Michael M. Goodin(University of Kentucky), Layne W. Rogers(Duke University), Xiaodi Qin(Duke Cancer Institute), Pixu Shi(University of Pittsburgh), Alexander B. Sibley(Duke University)
Cited by 9
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917